You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

Details for Patent: 10,278,969


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,278,969 protect, and when does it expire?

Patent 10,278,969 protects TRUSELTIQ and is included in one NDA.

This patent has forty-four patent family members in thirty-three countries.

Summary for Patent: 10,278,969
Title:Pharmaceutical dosage forms
Abstract: The present invention relates to solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-ph- enylamino]-pyrimidin-4-yl}-1-methyl-urea or any pharmaceutically acceptable salt thereof. It further relates to processes of making said solid pharmaceutical dosage forms.
Inventor(s): Ribeiro; Suzie (Basel, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:15/102,378
Patent Claim Types:
see list of patent claims
Compound; Dosage form;

Drugs Protected by US Patent 10,278,969

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Helsinn Hlthcare TRUSELTIQ infigratinib phosphate CAPSULE;ORAL 214622-001 May 28, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Helsinn Hlthcare TRUSELTIQ infigratinib phosphate CAPSULE;ORAL 214622-002 May 28, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,278,969

PCT Information
PCT FiledDecember 11, 2014PCT Application Number:PCT/IB2014/066820
PCT Publication Date:June 18, 2015PCT Publication Number: WO2015/087283

International Family Members for US Patent 10,278,969

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 098716 ⤷  Sign Up
Australia 2014362999 ⤷  Sign Up
Canada 2930055 ⤷  Sign Up
Chile 2016001436 ⤷  Sign Up
China 105813635 ⤷  Sign Up
China 116942629 ⤷  Sign Up
Cyprus 1122063 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.